Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995654 | 0.96 | LMNA (0.55) | LMNA | |
| Butane SCHEMBL3137845 | 0.86 | LMNA (0.48) | LMNA | |
| Dimethylformamide SCHEMBL133174 | 0.83 | LMNA (0.55) | LMNA | |
| Butane SCHEMBL11523278 | 0.82 | LMNA (0.44) | LMNA | |
| Butane SCHEMBL11540528 | 0.82 | LMNA (0.48) | LMNA | |
| Butane SCHEMBL11344980 | 0.81 | LMNA (0.43) | LMNA | |
| Butane SCHEMBL2557609 | 0.80 | LMNA (0.63) | LMNA | |
| Butane SCHEMBL818136 | 0.80 | LMNA (0.63) | LMNA | |
| Butane SCHEMBL10830357 | 0.79 | LMNA (0.50) | LMNA | |
| Butane SCHEMBL8312214 | 0.78 | LMNA (0.60) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206205-B1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE BEIJING CO LTD (CN) | 2026-03-04 | — | — | EP | claimed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| WO-2022042577-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | 北京普祺医药科技有限公司 | 2022-03-03 | — | — | WO | claimed |
| CN-103030598-B | The preparation method of methoxy acrylic bactericide | SHANGHAI HEBEN PHARMACEUTICAL CO., LTD. (CN) | 2016-04-13 | — | — | CN | claimed |
| CN-103626691-B | The preparation method of ZEN 90160 | Shanghai Heben-Eastsun Medicaments Co., Ltd. (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-104151233-A | Preparation method of agricultural bactericide | ZHEJIANG TIDE CROP TECHNOLOGY CO LTD | 2014-11-19 | — | — | CN | claimed |
| CN-103626691-A | Picoxystrobin preparation method | SHANGHAI HEBEN EASTSUN MEDICAMENTS CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-103030598-A | Method for preparing strobilurin fungicide | SHANGHAI HEBEN EASTSUN MEDICAMENTS CO LTD | 2013-04-10 | — | — | CN | claimed |
| EP-4206205-B1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE BEIJING CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025047698-A1 | PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, METHOD FOR PRODUCING SAME, LIQUID CRYSTAL DEVICE, SEMICONDUCTOR DEVICE, POLYMER, AND COMPOUND | JSR株式会社 | 2025-03-06 | — | — | WO | disclosed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022042577-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | 北京普祺医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0163599-A2 | Pyrimidopyrimidine derivatives, processes for producing them, pharmaceutical compositions containing them and their use as anti-allergic agents | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1985-12-04 | — | — | EP | disclosed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | disclosed |
| US-4175087-A | ENAMINOKETONES WITH ALKYLLITHIUM | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | DPYD, RPLP2, DHPS | LMNA 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.